{
    "symbol": "ITCI",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-03 14:42:05",
    "content": "  These statements may include statements regarding, among other things, the efficacy, safety and intended use of the company's product development candidates, our clinical and nonclinical plans, our plans to present and report additional data, the anticipated conduct and results of ongoing and future clinical trials, plans regarding regulatory filings, future research and development, our plans and expectations regarding the commercialization of CAPLYTA; potential impact of COVID-19 pandemic on our business; and possible uses of existing cash and investment resources."
}